ARTICLE | Clinical News
Berlex starts Crohn's Phase IIIs
June 30, 2004 7:00 AM UTC
Schering (FSE:SCH; SHR) subsidiary Berlex started two double-blind, placebo-controlled Phase III trials (NOVEL 3 and 4) of Leukine sargramostim to treat Crohn's disease. Recruitment also is underway i...